A structurally stable, injectable, & immunocompetent human skin model to assess immunogenicity of therapeutic compounds (White Paper)
SIGN IN
Improve Toxicity Assessments with Human-Related Information
Uncover how superior ex vivo human pores and skin fashions are reshaping toxicity evaluations for therapeutic compounds. This white paper highlights progressive strategies to evaluate immunogenicity, showcasing knowledge offered by Dr. Nicolas Gaudenzio, Genoskin’s Chief Scientific Officer, on the FDA-CRCG Peptide Immunogenicity Workshop in October.
Utilizing Genoskin’s sturdy platforms, we offer insights to de-risk therapeutic candidates and help non-clinical security and toxicity assessments, enabling knowledgeable decision-making with confidence.
Key highlights embody:
- Immunocompetent human pores and skin fashions: Preserve viability and immune integrity for over 7 days, permitting for the detection of undesirable immune reactions earlier within the drug improvement course of.
- Transcriptomic profiling: Establish adjustments in gene expression and immune responses crucial for understanding compound security.
- Validated workflows for injectables: From subcutaneous, intradermal and transdermal supply, guarantee dependable and reproducible testing.
- mRNA vaccine administration: Case research illustrates the power to seize fast immune responses post-injection.
By leveraging human-relevant fashions and cutting-edge companies, we provide scalable, actionable insights tailor-made to your improvement wants, serving to you scale back reliance on animal testing whereas accelerating therapeutic innovation.
Obtain the white paper now to discover how our companies can help your subsequent breakthrough.
Trending Merchandise
